Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Share-based Compensation (2016 - 2025)

CytomX Therapeutics' Share-based Compensation history spans 12 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 21.5% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $2.8 million, down 55.12%, while the annual FY2025 figure was $6.3 million, 17.81% down from the prior year.
  • Share-based Compensation reached $1.5 million in Q4 2025 per CTMX's latest filing, up from $597000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.5 million in Q4 2021 to a low of -$9.6 million in Q4 2022.
  • Average Share-based Compensation over 5 years is $1.2 million, with a median of $1.9 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: tumbled 369.61% in 2022, then skyrocketed 400.0% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $3.5 million in 2021, then crashed by 369.61% to -$9.6 million in 2022, then surged by 126.71% to $2.6 million in 2023, then decreased by 26.18% to $1.9 million in 2024, then decreased by 21.5% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Share-based Compensation are $1.5 million (Q4 2025), $597000.0 (Q3 2025), and $200000.0 (Q2 2025).